Romiplostim 750 µg [clinicaltrials_resource:NCT00413283/group/E4]
Participants received romiplostim 750 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.
Hyperlipidaemia for NCT00413283 for E4 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/100/count/400]Hypoglycaemia for NCT00413283 for E4 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/101/count/404]Hypokalaemia for NCT00413283 for E4 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/102/count/408]Hypomagnesaemia for NCT00413283 for E4 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/103/count/412]Hyponatraemia for NCT00413283 for E4 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/104/count/416]Arthralgia for NCT00413283 for E4 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/105/count/420]Back pain for NCT00413283 for E4 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/106/count/424]Bone pain for NCT00413283 for E4 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/107/count/428]Joint swelling for NCT00413283 for E4 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/108/count/432]Muscle fatigue for NCT00413283 for E4 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/109/count/436]Muscular weakness for NCT00413283 for E4 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/110/count/440]Musculoskeletal chest pain for NCT00413283 for E4 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/111/count/444]Musculoskeletal pain for NCT00413283 for E4 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/112/count/448]Myalgia for NCT00413283 for E4 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/113/count/452]Pain in extremity for NCT00413283 for E4 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/114/count/456]Cancer pain for NCT00413283 for E4 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/115/count/460]Amnesia for NCT00413283 for E4 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/116/count/464]Burning sensation for NCT00413283 for E4 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/117/count/468]Dizziness for NCT00413283 for E4 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/118/count/472]Headache for NCT00413283 for E4 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/119/count/476]Hypoaesthesia for NCT00413283 for E4 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/120/count/480]Neuropathy peripheral for NCT00413283 for E4 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/121/count/484]Paraesthesia for NCT00413283 for E4 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/122/count/488]Syncope for NCT00413283 for E4 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/123/count/492]Tremor for NCT00413283 for E4 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/124/count/496]Confusional state for NCT00413283 for E4 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/125/count/500]Depression for NCT00413283 for E4 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/126/count/504]Insomnia for NCT00413283 for E4 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/127/count/508]Restlessness for NCT00413283 for E4 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/128/count/512]Haematuria for NCT00413283 for E4 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/129/count/516]Nocturia for NCT00413283 for E4 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/130/count/520]Renal failure for NCT00413283 for E4 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/131/count/524]Renal pain for NCT00413283 for E4 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/132/count/528]Urinary incontinence for NCT00413283 for E4 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/133/count/532]Chronic obstructive pulmonary disease for NCT00413283 for E4 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/134/count/536]Cough for NCT00413283 for E4 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/135/count/540]Dyspnoea for NCT00413283 for E4 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/136/count/544]Epistaxis for NCT00413283 for E4 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/137/count/548]Haemoptysis for NCT00413283 for E4 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/138/count/552]Pleural effusion for NCT00413283 for E4 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/139/count/556]
group [clinicaltrials_vocabulary:group]
Romiplostim 750 µg [clinicaltrials_resource:NCT00413283/group/E4]
Participants received romiplostim 750 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.
Bio2RDF identifier
NCT00413283/group/E4
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:NCT00413283/group/E4
group id [clinicaltrials_vocabulary:group-id]
description
Participants received romiplos ...... andard institutional practice.
@en
identifier
clinicaltrials_resource:NCT00413283/group/E4
title
Romiplostim 750 µg
@en
type
label
Romiplostim 750 µg [clinicaltrials_resource:NCT00413283/group/E4]
@en